Every material Form 8-K Amneal Pharmaceuticals has filed with the SEC since February 28, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Amneal reported third-quarter 2026 net revenue of $863 million, up 10%, and Adjusted EBITDA of $207 million, up 30%, but swung to a GAAP net loss of $22 million from net income a year earlier, driven by acquisition and integration costs and a higher tax provision. The company raised its full-year 2026 revenue, Adjusted EBITDA and adjusted EPS guidance, while lowering its operating cash flow guidance, which it attributed to higher inventory levels.
Q3 2026 net revenue was $863 million, up from $785 million in Q3 2025; Adjusted EBITDA was $207 million, up 30%.
GAAP net loss attributable to Amneal was $22 million, or $(0.06) per diluted share, compared with net income of $2 million a year earlier; adjusted diluted EPS was $0.26, up 53% from $0.17.
Full-year 2026 net revenue guidance rose to $3.15 billion to $3.25 billion from $3.10 billion to $3.20 billion; Adjusted EBITDA guidance rose to $800 million to $815 million from $750 million to $780 million.
Operating cash flow guidance was lowered to $325 million to $375 million from $350 million to $400 million, reflecting working capital, including higher inventory levels.
Amneal Pharmaceuticals completed its acquisition of Kashiv BioSciences on August 10, 2026, paying in part with 28,942,098 newly issued Class A shares. The company also borrowed a $350 million incremental term loan, with proceeds used as part of the purchase consideration, and says the deal adds a long-term biosimilars growth pillar. The filing does not disclose financial results or the total purchase price, so the effect on earnings and the share count is not yet quantified.
Acquisition of Kashiv BioSciences, LLC closed on August 10, 2026, under a Membership Interest Purchase Agreement dated April 21, 2026
Amneal issued 28,942,098 shares of Class A Common Stock to the sellers in a private placement exempt from registration
$350 million incremental term loan made by Bank of America, N.A. under Amendment No. 4 to the Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as agent
Amneal plans to file Kashiv financial statements and pro forma information by amendment, and to register the shares for resale on Form S-3
Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, reducing the interest rate margin on its term loans by 50 basis points. The company estimates annualized cash interest savings of approximately $12 million compared with the prior agreement, based on amounts outstanding before the amendment.
Existing term loans converted into new term loans with an aggregate principal amount of $2.039 billion
A new $45.2 million term loan was incurred, with proceeds used to prepay remaining existing term loans at par
Margin reduced to 1.50% for base rate loans and 2.50% for SOFR-based loans; stated maturity remains August 1, 2032
Estimated annualized cash interest savings of approximately $12 million; no prepayment premium on a repricing after February 3, 2027
Amneal reported second-quarter 2026 net revenue of $796 million, up 10% from $725 million a year earlier, and GAAP net income attributable to the company of $58 million, up from $22 million. The company raised its full-year 2026 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, and said a July term loan repricing is expected to cut annual cash interest by about $12 million.
Q2 2026 net revenue was $796 million, up 10%; Specialty rose 17%, Affordable Medicines rose 13%, and AvKARE fell 4%.
GAAP diluted EPS was $0.18 versus $0.07 a year earlier; adjusted diluted EPS was $0.30 versus $0.25, up 20%.
Adjusted EBITDA was $206 million, up 12% from the second quarter of 2025.
2026 guidance raised: net revenue $3.10 billion to $3.20 billion (prior $3.05 billion to $3.15 billion); adjusted diluted EPS $0.96 to $1.06 (prior $0.95 to $1.05).
Amneal Pharmaceuticals reported first-quarter 2026 net revenue of $723 million, up 4% from $695 million a year earlier, and GAAP net income attributable to the company of $62 million, up from $12 million. The company affirmed the full-year 2026 guidance it raised on April 22, 2026, which calls for net revenue of $3.05 billion to $3.15 billion and adjusted diluted EPS of $0.95 to $1.05.
Q1 2026 diluted EPS was $0.19 versus $0.04 in Q1 2025; adjusted diluted EPS was $0.27, up 29%.
Adjusted EBITDA was $202 million, up 19% from $170 million in Q1 2025.
Specialty net revenue rose 23%, while AvKARE net revenue fell 4%.
Net cash used in operating activities was $26.7 million in Q1 2026, compared with $7.4 million provided in Q1 2025.
Amneal agreed on April 21, 2026 to acquire 100% of Kashiv BioSciences, LLC for $375 million in cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments and royalties. The same day, Amneal reported preliminary first quarter 2026 results showing higher revenue, net income and EPS, and raised its 2026 adjusted EBITDA and adjusted diluted EPS guidance.
Consideration: $375 million cash and 28,942,108 Class A shares at closing, plus up to $350 million in contingent regulatory milestone payments; closing expected in the second half of 2026 and requires Amneal shareholder approval.
Preliminary Q1 2026 (unaudited): consolidated net revenue $723 million, up 4% from $695 million; net income $78 million versus $25 million; diluted EPS $0.19 versus $0.04.
Raised 2026 adjusted EBITDA guidance to $740 million-$770 million from $720 million-$760 million; adjusted diluted EPS to $0.95-$1.05 from $0.93-$1.03; net revenue guidance unchanged at $3.05 billion-$3.15 billion.
Acquisition agreement has an outside date of November 17, 2026, extendable to January 12, 2027 if only certain regulatory approvals remain outstanding.
Amneal Pharmaceuticals reported fourth-quarter 2025 net revenue of $814 million, up 11% from a year earlier, and GAAP net income attributable to the company of $35 million, compared with a loss of $31 million in the fourth quarter of 2024. For the full year, revenue rose 8% to $3.02 billion and adjusted diluted EPS was $0.83, and the company gave 2026 guidance of $3.05 billion to $3.15 billion in net revenue and $0.93 to $1.03 in adjusted diluted EPS, which is above 2025 results.
Q4 2025 net revenue was $814 million, up 11%, with Specialty up 38% and Affordable Medicines down 1%
Q4 2025 GAAP diluted EPS was $0.11 versus a loss of $0.10 a year earlier; adjusted diluted EPS was $0.21 versus $0.12
Full year 2025 net revenue was $3.02 billion and adjusted EBITDA was $688 million, up 10%
2026 guidance: net revenue of $3.05 billion to $3.15 billion, adjusted EBITDA of $720 million to $760 million, adjusted diluted EPS of $0.93 to $1.03
On February 2, 2026, subsidiary Amneal Pharmaceuticals LLC amended its term loan credit agreement with JPMorgan Chase Bank, N.A. as administrative agent. Existing loans were converted into new term loans of $1,960,076,527.50, and a new term loan of $134,673,472.50 was added, with proceeds used to prepay the remaining existing loans. The company estimates annualized cash interest savings of approximately $11 million, and the August 1, 2032 maturity is unchanged.
Interest margin reduced by 50 basis points to 2.00% (base rate loans) and 3.00% (SOFR-based loans)
Converted term loans totaling $1,960,076,527.50 and a new term loan of $134,673,472.50
Estimated annualized cash interest savings of approximately $11 million; maturity remains August 1, 2032
Amendment allows a repricing transaction without a prepayment premium after August 2, 2026
Amneal Pharmaceuticals said in a January 13, 2026 investor presentation filing that it expects to meet or exceed the 2025 full-year financial guidance it gave on October 30, 2025. It also estimates net leverage of about 3.6x as of December 31, 2025, down from 3.9x a year earlier. The filing reaffirms the existing guidance ranges rather than raising them, and the figures remain estimates subject to year-end close.
Guidance ranges unchanged from October 30, 2025: net revenue $3.0 billion to $3.1 billion and adjusted diluted EPS $0.75 to $0.80
Adjusted EBITDA guidance of $675 million to $685 million; operating cash flow guidance of $300 million to $330 million
Estimated net leverage of approximately 3.6x as of December 31, 2025, compared with 3.9x as of December 31, 2024
Figures are based on current estimates and remain subject to change until year- and quarter-end closing processes are complete
Amneal reported third-quarter 2025 net revenue of $785 million, up 12% from $702 million a year earlier, and GAAP net income attributable to the company of $2 million, or $0.01 per diluted share, compared with a loss in the prior-year quarter. The company raised its 2025 adjusted EBITDA, adjusted diluted EPS and operating cash flow guidance and left net revenue guidance unchanged, while a $31.4 million loss on refinancing weighed on quarterly results.
Net revenue was $785 million, up 12%; Specialty rose 8%, Affordable Medicines rose 8% and AvKARE rose 24%.
GAAP net income attributable to Amneal was $2 million ($0.01 per diluted share); adjusted diluted EPS was $0.17, up 6% from $0.16.
2025 adjusted diluted EPS guidance was raised to $0.75-$0.80 from $0.70-$0.75, and adjusted EBITDA guidance to $675-$685 million from $665-$685 million.
The quarter included a $31.4 million loss on refinancing tied to the August 1, 2025 borrowing of $2.1 billion in term loans and $600 million of senior notes due 2032.
Amneal Pharmaceuticals reported second-quarter 2025 net revenue of $725 million, up 3% from a year earlier, and GAAP net income attributable to the company of $22 million, up from $6 million. The company raised its full-year 2025 adjusted EBITDA and adjusted diluted EPS guidance, while keeping net revenue guidance unchanged, and completed a debt refinancing that it says extends maturities to 2032.
Q2 2025 net revenue was $725 million, up 3% from $702 million; GAAP diluted EPS was $0.07 versus $0.02, and adjusted diluted EPS was $0.25, up 56%.
Adjusted EBITDA was $184 million, up 13% from the second quarter of 2024.
2025 guidance: adjusted EBITDA raised to $665 million-$685 million from $650 million-$675 million; adjusted diluted EPS raised to $0.70-$0.75 from $0.65-$0.70; net revenue unchanged at $3.0 billion-$3.1 billion.
On August 1, 2025, the company completed $2.1 billion of new seven-year Term B loans and $600 million of 6.875% senior secured notes due 2032, used to refinance prior debt.
On August 1, 2025, Amneal Pharmaceuticals LLC borrowed $2.1 billion of new seven-year term loans and completed a $600 million offering of 6.875% senior secured notes due 2032. The company used the proceeds to refinance its existing term loans, which had about $2.26 billion outstanding, and to repay its ABL facility in full. The filing describes a refinancing that replaces existing debt and extends maturities rather than adding a stated new use of cash.
New $2.1 billion term loan matures August 1, 2032, with interest at term SOFR plus a 3.50% margin
$600 million of 6.875% senior secured notes due August 1, 2032, issued at 100% of principal amount
Existing term loan of about $2.26 billion refinanced in full; ABL facility repaid and its maturity extended to August 1, 2030 with $600 million of commitments
Amneal Pharmaceuticals released unaudited preliminary second-quarter 2025 results, with net revenue of $720 million to $730 million and adjusted EBITDA of $180 million to $185 million, both up versus the same period in 2024. The company said it expects to meet or exceed its full-year 2025 guidance, and the figures may change before the final results due August 5, 2025. Separately, director Emily Peterson Alva resigned from the Board and its Audit Committee, effective immediately, which the company said was not due to any disagreement.
Net revenue of $720 million to $730 million, up about 3% from the same period in 2024
Adjusted EBITDA of $180 million to $185 million, up about 13%; income before income taxes of $45 million to $56 million versus $20 million a year earlier
Gross leverage fell to 3.8x and net leverage to 3.7x as of June 30, 2025, from 4.1x and 3.9x at December 31, 2024
Emily Peterson Alva, an Amneal Group designee, resigned from the Board on July 16, 2025; the Amneal Group's board designation right was reduced from six to five
Amneal Pharmaceuticals reported first-quarter 2025 net revenue of $695 million, up 5% from $659 million a year earlier, and net income attributable to the company of $12 million, compared with a net loss of $92 million in the first quarter of 2024. The company reaffirmed its full-year 2025 guidance, including net revenue of $3.0 billion to $3.1 billion and adjusted diluted EPS of $0.65 to $0.70, so shareholders see improved results with no change to the outlook.
Net revenue $695 million, up 5% from $659 million; Affordable Medicines up 6%, Specialty up 3%, AvKARE up 6%
GAAP diluted EPS $0.04 versus a loss of $0.30; adjusted diluted EPS $0.21, up 50% from $0.14
Adjusted EBITDA $170 million, up 12% from the prior-year quarter
Full-year 2025 guidance affirmed: adjusted EBITDA $650 million to $675 million; conference call at 8:30 am Eastern on May 2, 2025
Amneal Pharmaceuticals entered into an employment agreement with Jason Daly, its Chief Legal Officer and Corporate Secretary, effective March 1, 2025, which sets his title as Executive Vice President, Chief Legal Officer & Corporate Secretary. The agreement covers a $575,000 base salary, a target bonus of 55% of base salary, and severance terms that include enhanced protections tied to a change in control.
Annual base salary of $575,000, effective March 1, 2025
Target annual bonus equal to 55% of base salary, with a personal performance multiplier of zero to 150% of that amount
Severance on termination without cause or for good reason: 150% of base salary, prorated bonus, 18 months of benefits continuation and 12 months of outplacement assistance
Initial term runs until March 31, 2027, with automatic one-year renewals absent 90 days' notice of non-renewal
Amneal reported fourth-quarter and full-year 2024 results on February 28, 2025. Net revenue rose 18% in the quarter and 17% for the year, while the GAAP net loss narrowed in the quarter but widened for the full year, and adjusted diluted EPS declined. The company also gave 2025 guidance for net revenue of $3.0 billion to $3.1 billion and adjusted EBITDA of $650 million to $675 million.
Q4 2024 net revenue was $731 million, up 18% from $617 million; GAAP net loss attributable to Amneal was $31 million, versus $99 million in Q4 2023.
Q4 2024 adjusted diluted EPS was $0.12, compared with $0.14 in Q4 2023.
Full-year 2024 net revenue was $2.79 billion, up 17%; GAAP net loss was $117 million, versus $84 million in 2023; adjusted diluted EPS was $0.58, down 9%.
2025 guidance: net revenue of $3.0 billion to $3.1 billion, adjusted EBITDA of $650 million to $675 million, and adjusted diluted EPS of $0.65 to $0.70.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Amneal Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →